Press Releases April 22, 2026 04:10 PM

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

RxSight to Report Q1 2026 Financial Results on May 6 with Management Conference Call

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
RXST

RxSight, Inc., a NASDAQ-listed ophthalmic medical device company specializing in adjustable intraocular lenses for cataract surgery, announced it will report its Q1 2026 financial results after market close on May 6, 2026 and hold a conference call for investors.

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RXST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Announcement of first quarter 2026 financial results release on May 6, 2026 after market close.
  • Management will hold a conference call to discuss the results, accessible via phone and webcast.
  • RxSight develops and markets the Light Adjustable Lens system, a customizable intraocular lens technology for cataract surgery patients.

ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
[email protected]


Risks

  • Financial results could show weaker-than-expected performance impacting stock price.
  • Dependence on the adoption and market acceptance of the Light Adjustable Lens technology in ophthalmic surgery.
  • Risks related to market competition and regulatory approvals in the medical device sector.

More from Press Releases

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026 Traws Pharma Provides Regulatory Update on Influenza Program Jun 12, 2026 Heartland Express, Inc. Declares Regular Quarterly Dividend Jun 12, 2026